Symic Bio
Latest round
- Series B
Last raised
- May 2017
Total raised
- $70M
Investors
- 9
About Symic Bio
Symic Bio, Inc.Founded in 2012 and based in Emeryville, US, Symic Bio, Inc. specializes in creating improved drug formulations.Symic Bio specializes in the development of innovative therapies designed to enhance the safety and efficacy of existing treatments in the medical field. The company’s core product offerings focus on unique therapeutic platforms that leverage their proprietary technology to create improved versions of drugs targeting various medical conditions, including but not limited to cancer and cardiovascular diseases. These offerings are developed to address critical end-use cases such as increasing drug half-life, ensuring targeted delivery, and reducing side effects, which are significant challenges in conventional treatments.Symic Bio's revenue model is primarily based on collaborations, licensing agreements, and partnerships with pharmaceutical companies that are looking to enhance their product portfolios with innovative therapies. The structure typically involves upfront payments for access to Symic Bio's proprietary technology, followed by milestone payments linked to the progress of drug development and eventual royalties on sales of the developed products. The company’s flagship products, developed through these partnerships, are expected to command premium pricing in the market due to their advanced therapeutic benefits.00 mn in May 2017, Symic Bio plans to utilize the funds to further develop its innovative therapies and expand its market presence. The company aims to launch new products targeting critical medical conditions, although specific release dates are not disclosed. Additionally, Symic Bio is looking to expand into new markets, particularly in Europe and Asia, by 2025, to meet the increasing demand for advanced therapeutic solutions. This strategic growth is focused on enhancing their product offerings and strengthening partnerships in the biopharmaceutical sector.
Who invested in Symic Bio
9 investors across 3 rounds
See all investors in Symic Bio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Symic Bio
Who invested in Symic Bio?
Symic Bio has 9 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Symic Bio raised?
Symic Bio has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Symic Bio last raise money?
Symic Bio's most recent round on record is a Series B, in May 2017.
What does Symic Bio do?
Symic Bio is a pharmaceuticals company.
Where is Symic Bio headquartered?
Symic Bio is headquartered in Emeryville, US.
Which VCs invest in companies like Symic Bio?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at Symic Bio's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series B
Raising like Symic Bio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.